CTOs on the Move

Virpax Pharmaceuticals

www.virpaxpharma.com

 
Virpax`s lead product candidate, Probudur, is being developed using our proprietary liposomal encapsulation to deliver a sustain release of local anesthetic at the wound/incision site to control post-operative pain for 96 hours. We have executed Cooperative Research and Development Agreements (CRADA), as well as the National Institute of Health/NCATS; U.S. Army Institute of Surgical Research/Department of Defense to develop differentiated non-addictive treatment options and the Epilepsy Therapy Screening Program (ETSP) which is focused on focused on addressing drug resistant epilepsy, disease prevention and modification. The three products in development are targeting unmet global needs in three separate multi-billion-dollar markets, including ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Virpax Pharmaceuticals raised $18M on 02/16/2021

Similar Companies

Graceway Pharmaceuticals

Graceway Pharmaceuticals is a Bristol, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sinoveda

Sinoveda is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Institute for OneWorld Health

Institute for OneWorld Health is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.

Rainier Therapeutics

Rainier is a uniquely diverse manufacturing company, producing a variety of display, shelter, fabric and shading products. Our mission is to create the highest quality available in everything we create--using the best technology and materials. Rainier consistently meets demanding requirements--and we`re at our best creating new solutions.